A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.

被引：0
|
作者：
Kim, Won Seog
Yoon, Dok Hyun
Song, Yuqin
Yang, Haiyan
Cao, Junning
Ji, Dongmei
Koh, Youngil
Jing, Hongmei
Eom, Hyeon Seok
Kwak, Jae-Yong
Lee, Won-Sik
Lee, Jong Seok
Shin, Ho-Jin
Jin, Jie
Wang, Mei
Li, Jingrun
Huang, Xubin
Deng, Xueyuan
Yang, Zhenfan
Zhu, Jun
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[3] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[7] Peking Univ Third Hosp, Beijing, Peoples R China
[8] Natl Canc Ctr, Goyang, South Korea
[9] Chonbuk Natl Univ Hosp, Jeonju Si, South Korea
[10] Inje Univ, Busan Paik Hosp, Busan, South Korea
[11] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[12] Pusan Natl Univ Hosp, Pusan, South Korea
[13] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Dizal Pharmaceut, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7563
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 7 - 9
  • [22] The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
    Horwitz, Steven M.
    Feldman, Tatyana A.
    Hess, Brian T.
    Khodadoust, Michael S.
    Kim, Youn H.
    Munoz, Javier
    Patel, Manish R.
    Phillips, Tycel J.
    Smith, Stephen D.
    Smith, Sonali M.
    Wilcox, Ryan A.
    Steele, Andrew
    Pandey, Anjali
    Birrell, Matt R.
    Leeds, Janet M.
    Conley, Pamela B.
    Michelson, Glenn
    Coffey, Gregory P.
    Curnutte, John T.
    Hamlin, Paul A.
    BLOOD, 2018, 132
  • [23] A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Jin, Jie
    Cen, Hong
    Zhou, Keshu
    Xu, Xiaohong
    Li, Fei
    Yang, Haiyan
    Li, Zhiming
    Bao, Hanying
    Xu, Zusheng
    Qiu, Lugui
    Shu, Yang
    Li, Fei
    Wang, Zhen
    BLOOD, 2021, 138
  • [24] Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).
    Cai, Qingqing
    Zhu, Jun
    Song, Yuqin
    Zhao, Weili
    Zhou, Keshu
    Wu, Jianqiu
    Zhang, Huilai
    Malpica, Luis
    Ding, Kaiyang
    Liu, Yao
    Li, Zengjun
    Zhang, Liling
    Zheng, Meifang
    Jin, Jie
    Yang, Haiyan
    Shuang, Yuerong
    Yoon, Dok Hyun
    Gao, Sujun
    Yu, Wenlei
    Kim, Won Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Trial in Progress: A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
    Groarke, Emma M.
    Lotter, Jennifer
    Darden, Ivana
    Bikineyeva, Alfiya
    Okeke, Uzoamaka
    Blair, Rachel
    Erb-Alvarez, Julie
    Chen, Jichun
    Feng, Xingmin
    Durrani, Jibran
    Young, Neal S.
    Patel, Bhavisha A.
    BLOOD, 2024, 144
  • [26] Phase II study of enzastaurin in the treatment of relapsed/refractory mantle cell lymphoma.
    Morschhausser, Frank
    Wolf, Martin
    Seymour, John
    Tilly, Herve
    Pfreundschuh, Michael
    Kluin-Nelemans, Hanneke
    Raemaekers, John
    van't Veer, Mars B.
    Milpied, Noel
    Cartron, Guillaume
    Pezzutto, Antonio
    Spencer, Andrew
    Darstein, Christelle
    Thornton, Donald
    Dreyling, Martin
    Reyes, Felix
    BLOOD, 2006, 108 (11) : 694A - 694A
  • [27] A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
    Van Den Neste, Eric W.
    Andre, Marc
    Gastinne, Thomas
    Stamatoullas, Aspasia
    Haioun, Corinne
    Belhabri, Amine
    Reman, Oumedaly
    Casasnovas, Olivier
    Ghesquieres, Herve
    Verhoef, Gregor
    Claessen, Marie-Jose
    Poirel, Helene A.
    Copin, Marie-Christine
    Dubois, Romain
    Vandenberghe, Peter
    Stoian, Ioanna-Andrea
    Cottereau, Anne Segolene
    Knoops, Laurent
    Morschhauser, Franck
    BLOOD, 2016, 128 (22)
  • [28] Phase I/II trial of infusional vinorelbine in relapsed or refractory lymphoma.
    Sarris, AH
    Psyrri, A
    Romaguera, J
    Hagemeister, F
    McLaughlin, P
    Bachier, C
    Mesina, O
    Adams, LM
    Cabanillas, F
    BLOOD, 1998, 92 (10) : 621A - 621A
  • [29] Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma
    Coiffier, Bertrand
    Pro, Barbara
    Prince, H. Miles
    Foss, Francine M.
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Borchmann, Peter
    Morschhauser, Franck
    Wilhelm, Martin
    Pinter-Brown, Lauren
    Padmanabhan, Swaminathan
    Shustov, Andrei R.
    Nichols, Jean
    Carroll, Susan
    Balser, John
    Horwitz, Steven M.
    BLOOD, 2011, 118 (21) : 272 - 272
  • [30] A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma
    Jin, Jie
    Cen, Hong
    Zhou, Keshu
    Xu, Xiaohong
    Li, Fei
    Wu, Tao
    Yang, Haiyan
    Wang, Zhen
    Li, Zhiming
    Huang, Wenyang
    Bao, Hanying
    Xu, Zusheng
    Qiu, Lugui
    CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4593 - 4600
12345